Read PLR Content Marketing South Africa: September 2016

Friday, September 16, 2016

Pepcid

Pepcid is a brand name of famotidine, approved by the FDA in the following formulation(s):

PEPCID (famotidine - for suspension; oral)

Manufacturer: SALIX PHARMS

Approval date: February 2, 1987

Strength(s): 40MG/5ML ^[RLD]^[AB]

PEPCID (famotidine - tablet; oral)

Manufacturer: MARATHON PHARMS

Approval date: October 15, 1986

Strength(s): 20MG ^[AB], 40MG ^[RLD]^[AB]

Has a generic version of Pepcid been approved?

Yes. The following products are equivalent to Pepcid:

famotidine for suspension; oral

Manufacturer: LUPIN LTD

Approval date: June 29, 2010

Strength(s): 40MG/5ML ^[AB]

Manufacturer: NAVINTA LLC

Approval date: May 27, 2010

Strength(s): 40MG/5ML ^[AB]

famotidine tablet; oral

Manufacturer: ALEMBIC PHARMS LTD

Approval date: May 22, 2009

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: APOTEX

Approval date: July 23, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: CARLSBAD

Approval date: April 16, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: DR REDDYS LABS LTD

Approval date: April 16, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: IVAX SUB TEVA PHARMS

Approval date: April 16, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: MYLAN

Approval date: April 16, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: MYLAN

Approval date: April 18, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: PERRIGO

Approval date: July 27, 2005

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: SANDOZ

Approval date: May 10, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: TEVA

Approval date: April 16, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: WATSON LABS

Approval date: April 16, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Manufacturer: WOCKHARDT

Approval date: April 16, 2001

Strength(s): 20MG ^[AB], 40MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pepcid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Pepcid.

Has a generic version of H.P. Acthar Gel been approved?

No. There is currently no therapeutically equivalent version of H.P. Acthar Gel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of H.P. Acthar Gel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with H.P. Acthar Gel.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- October 15, 2017 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Thalitone been approved?

No. There is currently no therapeutically equivalent version of Thalitone available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Thalitone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Thalitone.

Has a generic version of Anaprox-DS been approved?

Yes. The following products are equivalent to Anaprox-DS:

naproxen sodium tablet; oral

Manufacturer: AMNEAL PHARMS NY

Approval date: April 25, 2007

Strength(s): EQ 500MG BASE ^[AB]

Manufacturer: AUROBINDO PHARMA LTD

Approval date: October 31, 2011

Strength(s): EQ 500MG BASE ^[AB]

Manufacturer: DR REDDYS LABS LTD

Approval date: July 26, 2007

Strength(s): EQ 500MG BASE ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: April 27, 2007

Strength(s): EQ 500MG BASE ^[AB]

Manufacturer: HIKMA

Approval date: May 14, 1996

Strength(s): EQ 500MG BASE ^[AB]

Manufacturer: TEVA

Approval date: December 21, 1993

Strength(s): EQ 500MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: May 31, 1995

Strength(s): EQ 500MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anaprox-DS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Anaprox-DS.

Has a generic version of Acuvail been approved?

No. There is currently no therapeutically equivalent version of Acuvail available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Acuvail. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Ketorolac tromethamine compositions for treating ocular pain
Patent 7,842,714
Issued: November 30, 2010
Inventor(s): Farnes; Eldon Q. & Attar; Mayssa & Schiffman; Rhett M. & Chang; Chin-Ming & Graham; Richard S. & Welty; Devin F.
Assignee(s): Allergan, Inc.
The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
Patent expiration dates:
- August 15, 2029
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- July 22, 2012 - NEW PRODUCT

Has a generic version of Ofirmev been approved?

No. There is currently no therapeutically equivalent version of Ofirmev available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ofirmev. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Stable liquid paracetamol compositions, and method for preparing same
Patent 6,028,222
Issued: February 22, 2000
Inventor(s): Dietlin; Francois & Fredj; Daniele
Assignee(s): SCR Pharmatop
Novel stable paracetamol compositions for use in therapeutic chemistry and specifically galenic pharmacy are disclosed. The compositions contain a solution of paracetamol in an aqueous solvent combined with a buffer having a pH of 4 to 8, and a free radical capturing agent. A water-insoluble inert gas is carefully bubbled through the aqueous solvent to remove oxygen from the medium. Said compositions may also be combined with a centrally or peripherally acting analgesic agent, and are provided as injectable compositions for relieving pain.
Patent expiration dates:
- August 5, 2017
  ✓
  Drug product

Method for obtaining aqueous formulations of oxidation-sensitive active principles
Patent 6,992,218
Issued: January 31, 2006
Inventor(s): Dietlin; Francois & Fredj; Daniele
Assignee(s): Pharmatop SCR
A method for obtaining aqueous formulations with easily oxidizable active principles, notably phenols, stable over a prolonged period, comprising subjecting them to extreme deoxygenation by bubbling with an inert gas and/or placing wider vaccum, protecting them against possible resorption of oxygen by keeping them under an inert gas atmosphere, by filling, under inert gas, into bottles previously cleared of air by insufflation with inert gas, then subjecting them, while stoppering, to low pressure as obtained in the bottle, of 65,000 Pa maximum, to obtain aqueous solutions having a residual oxygen concentration in the solution below 2 ppm, and preferably of the order of 1 ppm and even 0.5 ppm useful as injectable preparations having an oxygen concentration in the solution below 2 ppm.
Patent expiration dates:
- June 6, 2021
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- November 2, 2013 - NEW PRODUCT

Has a generic version of Omnipaque 240 been approved?

No. There is currently no therapeutically equivalent version of Omnipaque 240 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Omnipaque 240. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Omnipaque 240.

Has a generic version of Optiray 320 been approved?

No. There is currently no therapeutically equivalent version of Optiray 320 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Optiray 320. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Optiray 320.

Has a generic version of Humatrope been approved?

No. There is currently no therapeutically equivalent version of Humatrope available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humatrope. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Humatrope.

Related Exclusivities

Exclusivity expiration dates:
- March 12, 2012 - TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
- November 1, 2013 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Humalog Mix 75/25 been approved?

No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Monomeric insulin analog formulations
Patent 5,461,031
Issued: October 24, 1995
Inventor(s): De Felippis; Michael R.
Assignee(s): Eli Lilly and Company
The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Patent expiration dates:
- June 16, 2014

Insulin analog formulations
Patent 5,474,978
Issued: December 12, 1995
Inventor(s): Bakaysa; Diane L. & Brems; David N. & Frank; Bruce H. & Havel; Henry A. & Pekar; Allen H.
Assignee(s): Eli Lilly and Company
The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
Patent expiration dates:
- June 16, 2014

Insulin analogs modified at position 29 of the B chain
Patent 5,514,646
Issued: May 7, 1996
Inventor(s): Chance; Ronald E. & DiMarchi; Richard D. & Frank; Bruce H. & Shields; James E.
Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
Patent expiration dates:
- May 7, 2013

Monomeric insulin analog formulations
Patent 5,747,642
Issued: May 5, 1998
Inventor(s): De Felippis; Michael R.
Assignee(s): Eli Lilly and Company
The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Patent expiration dates:
- June 16, 2014

Has a generic version of Humalog Mix 75/25 Pen been approved?

No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 Pen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25 Pen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Humalog Mix 75/25 Pen.

Has a generic version of Antivert been approved?

Yes. The following products are equivalent to Antivert:

meclizine hydrochloride tablet; oral

Manufacturer: AMNEAL PHARMS

Approval date: February 23, 2011

Strength(s): 12.5MG ^[AA], 25MG ^[AA], 50MG ^[AA]

Manufacturer: JUBILANT CADISTA

Approval date: June 4, 2010

Strength(s): 12.5MG ^[AA], 25MG ^[AA]

Manufacturer: PAR PHARM

Approved Prior to Jan 1, 1982

Strength(s): 12.5MG ^[AA], 25MG ^[AA]

Manufacturer: PAR PHARM

Approval date: March 31, 1988

Strength(s): 50MG ^[AA]

Manufacturer: SANDOZ

Approval date: May 22, 1989

Strength(s): 12.5MG ^[AA], 25MG ^[AA]

Manufacturer: VINTAGE PHARMS

Approval date: January 30, 1997

Strength(s): 12.5MG ^[AA], 25MG ^[AA]

Manufacturer: WATSON LABS

Approved Prior to Jan 1, 1982

Strength(s): 25MG ^[AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Antivert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Antivert.

Has a generic version of Allegra been approved?

No. There is currently no therapeutically equivalent version of Allegra available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Allegra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Piperidine derivatives
Patent 5,578,610
Issued: November 26, 1996
Inventor(s): D'Ambra; Thomas E.
Assignee(s): Albany Molecular Research, Inc.
The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
Patent expiration dates:
- November 26, 2013
  ✓
  Patent use: USE IN TREATING ALLERGIC REACTIONS
- November 26, 2013
  ✓
  Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
  ✓
  Drug substance
  ✓
  Drug product
- May 26, 2014
  ✓
  Patent use: USE IN TREATING ALLERGIC REACTIONS
  ✓
  Pediatric exclusivity

Pharmaceutical composition for piperidinoalkanol compounds
Patent 5,738,872
Issued: April 14, 1998
Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marquerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
Assignee(s): Hoechst Marion Roussel, Inc.
The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
Patent expiration dates:
- February 28, 2015
- August 28, 2015
  ✓
  Pediatric exclusivity

Pharmaceutical compositions for piperidinalkanol compounds
Patent 5,855,912
Issued: January 5, 1999
Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
Assignee(s): Hoechst Marion Roussel, Inc.
The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
Patent expiration dates:
- February 28, 2015
- August 28, 2015
  ✓
  Pediatric exclusivity

Pharmaceutical composition for piperidinoalkanol compounds
Patent 5,932,247
Issued: August 3, 1999
Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
Assignee(s): Hoechst Marion Roussel, Inc.
The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
Patent expiration dates:
- February 28, 2015
- August 28, 2015
  ✓
  Pediatric exclusivity

Method of providing an antihistaminic effect in a hepatically impaired patient
Patent 6,037,353
Issued: March 14, 2000
Inventor(s): Woodward; James K. & Okerholm; Richard A. & Eller; Mark G. & McNutt; Bruce E.
Assignee(s): Hoechst Marion Roussel, Inc.
The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
Patent expiration dates:
- March 14, 2017
  ✓
  Patent use: TREATMENT OF ALLERGIC RHINITIS
- March 14, 2017
  ✓
  Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
- September 14, 2017
  ✓
  Patent use: TREATMENT OF ALLERGIC RHINITIS
  ✓
  Pediatric exclusivity

Pharmaceutical composition for piperidinoalkanol compounds
Patent 6,113,942
Issued: September 5, 2000
Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
Assignee(s): Aventis Pharmaceuticals Inc.
The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
Patent expiration dates:
- February 28, 2015
- August 28, 2015
  ✓
  Pediatric exclusivity

Method of providing an antihistaminic effect in a hepatically impaired patient
Patent 6,187,791
Issued: February 13, 2001
Inventor(s): Woodward; James K. & Okerholm; Richard A. & Eller; Mark G. & McNutt; Bruce E.
Assignee(s): Merrell Pharmaceuticals Inc.
The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
Patent expiration dates:
- May 11, 2012
  ✓
  Patent use: TREATMENT OF ALLERGIC RHINITIS
- May 11, 2012
  ✓
  Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
- November 11, 2012
  ✓
  Patent use: TREATMENT OF ALLERGIC RHINITIS
  ✓
  Pediatric exclusivity

Method of providing an antihistaminic effect in a hepatically impaired patient
Patent 6,399,632
Issued: June 4, 2002
Inventor(s): James K.; Woodward & Richard A.; Okerholm & Mark G.; Eller & Bruce E.; McNutt
Assignee(s): Merrell Pharmaceuticals Inc.
The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; n is an integer of from 1 to 5; R3 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
Patent expiration dates:
- May 11, 2012
  ✓
  Patent use: METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- May 11, 2012
  ✓
  Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
- November 11, 2012
  ✓
  Patent use: METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
  ✓
  Pediatric exclusivity

Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
Patent 7,135,571
Issued: November 14, 2006
Inventor(s): Henton; Daniel R & McCarty; Frederick J & Tripp; Susan I & DeWitt; Jill E
Assignee(s): Aventis Pharmaceuticals, Inc.
The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulas which are useful as antihistamines, antiallergic agents and bronchodilators.
Patent expiration dates:
- May 18, 2014
  ✓
  Drug substance
- November 18, 2014
  ✓
  Pediatric exclusivity

Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
Patent 7,138,524
Issued: November 21, 2006
Inventor(s): McCarty; Frederick J. & Carr; Albert A.
Assignee(s): Aventis Pharmaceuticals, Inc.
The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulas which are useful as antihistamines, antiallergic agents and bronchodilators.
Patent expiration dates:
- May 18, 2014
  ✓
  Drug substance
- November 18, 2014
  ✓
  Pediatric exclusivity

Has a generic version of Minirin been approved?

Yes. The following products are equivalent to Minirin:

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) (desmopressin acetate spray, metered; nasal)

Manufacturer: APOTEX INC

Approval date: January 27, 2005

Strength(s): 0.01MG/SPRAY ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Minirin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Minirin.

Has a generic version of Prefest been approved?

A generic version of Prefest has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Prefest and have been approved by the FDA:

ESTRADIOL AND NORGESTIMATE (estradiol; norgestimate tablet; oral)

Manufacturer: BARR

Approval date: April 29, 2005

Strength(s): 1MG,1MG;N/A,0.09MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prefest. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Hormone preparation and method
Patent 5,382,573
Issued: January 17, 1995
Inventor(s): Casper; Robert F.
Assignee(s): Jencap Research Ltd.
This invention is concerned with a contraceptive formulation and a method of contraception which employs a combination of estrogen and progestin and wherein a short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The invention also concerns a hormonal replacement formulation and method for use in menopausal or castrate women which employs a similar combination of estrogen and progestin.
Patent expiration dates:
- January 17, 2012

Low dose estrogen interrupted hormone replacement therapy
Patent 6,747,019
Issued: June 8, 2004
Inventor(s): Robert F.; Casper & Gary A.; Shangold & Militza K.; Ausmanas
Assignee(s): Jencap Research, Ltd.
Ortho-McNeil Pharmaceutical, Inc.
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 &mgr;g per day of norgestimate.
Patent expiration dates:
- March 20, 2020
  ✓
  Patent use: HORMONE REPLACEMENT

Low dose estrogen interrupted hormone replacement therapy
Patent 7,320,970
Issued: January 22, 2008
Inventor(s): Casper; Robert F. & Shangold; Gary A. & Ausmanas; Militza K.
Assignee(s): Duramed Pharmaceutials, Inc.
Jencap Research Ltd.
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate.
Patent expiration dates:
- March 30, 2020
  ✓
  Patent use: PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
  ✓
  Drug product

Has a generic version of Alphagan P been approved?

A generic version of Alphagan P has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Alphagan P and have been approved by the FDA:

brimonidine tartrate solution/drops; ophthalmic

Manufacturer: ALCON PHARMS LTD

Approval date: May 22, 2006

Strength(s): 0.15% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alphagan P. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Aqueous ophthalmic formulations and methods for preserving same
Patent 5,424,078
Issued: June 13, 1995
Inventor(s): Dziabo; Anthony J. & Ripley; Paul S.
Assignee(s): Allergan, Inc.
Stabilized chlorine dioxide is a preservative for ophthalmic formulations. The stabilized chlorine dioxide, when employed as a preservative ophthalmic formulations is preferably present in an amount of from about 0.0002 or about 0.002 to about 0.02 weight/volume percent. The aqueous ophthalmic formulations, in addition to the stabilized chlorine dioxide and the water which functions as a vehicle for the formulations, contains an ophthalmically acceptable tonicity component effective to maintain the osmolality of the formulation at least about 200 mOsmol/kg, and a buffer to maintain the pH of the ophthalmic formulation within an acceptable physiological range. A method for preserving aqueous ophthalmic formulations utilizing stabilized chlorine dioxide is also set forth.
Patent expiration dates:
- June 13, 2012
  ✓
  Sponsor has requested patent be delisted
- June 13, 2012
  ✓
  Drug product
  ✓
  Sponsor has requested patent be delisted
- December 13, 2012
  ✓
  Pediatric exclusivity

Compositions containing therapeutically active components having enhanced solubility
Patent 6,562,873
Issued: May 13, 2003
Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
Assignee(s): Allergan, Inc.
Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
Patent expiration dates:
- July 10, 2021
- July 10, 2021
  ✓
  Drug product
- January 10, 2022
  ✓
  Pediatric exclusivity

Compositions containing &agr;-2-adrenergic agonist components
Patent 6,627,210
Issued: September 30, 2003
Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
Assignee(s): Allergan, Inc.
Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Patent expiration dates:
- July 18, 2021
  ✓
  Drug product
- January 18, 2022
  ✓
  Pediatric exclusivity

Compositions containing alpha-2-adrenergic agonist components
Patent 6,641,834
Issued: November 4, 2003
Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
Assignee(s): Allergan Sales, Inc.
Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Patent expiration dates:
- July 28, 2021
  ✓
  Drug product
- January 28, 2022
  ✓
  Pediatric exclusivity

Compositions containing alpha-2-adrenergic agonist components
Patent 6,673,337
Issued: January 6, 2004
Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
Assignee(s): Allergan, Inc.
Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
Patent expiration dates:
- July 26, 2021
  ✓
  Drug product
- January 26, 2022
  ✓
  Pediatric exclusivity

Has a generic version of Ammonul been approved?

No. There is currently no therapeutically equivalent version of Ammonul available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ammonul. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ammonul.

Related Exclusivities

Exclusivity expiration dates:
- February 17, 2012 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Abilify been approved?

No. There is currently no therapeutically equivalent version of Abilify available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Abilify. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Carbostyril derivatives
Patent 5,006,528
Issued: April 9, 1991
Inventor(s): Oshiro; Yasuo & Sato; Seiji & Kurahashi; Nobuyuki
Assignee(s): Otsuka Pharmaceutical Co., Ltd.
A novel carbostyril derivative and salt thereof represented by the formula (1) ##STR1## (wherein R is a group of the formula ##STR2## ((wherein R.sup.1 is a C.sub.1- C.sub.3 alkoxy group)), a group of the formula ##STR3## ((wherein R.sup.2 and R .sup.3 are each, at the same time, a chlorine atom, a bromine atom; and R.sup.4 is a hydrogen atom or a chlorine atom)), 2-methyl-3-nitrophenyl group, 3,5-dichlorophenyl group, or a group of the formula ##STR4## ((wherein R.sup.5 is a chlorine atom or a bromine atom; and R.sup.6 is a methyl group)); the carbon-carbon bond between 3- and 4-position in the carbostyril skeleton is a single or double bond).
Patent expiration dates:
- October 20, 2014
  ✓
  Patent use: TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
  ✓
  Drug substance
  ✓
  Drug product
- October 20, 2014
  ✓
  Patent use: ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
  ✓
  Drug substance
  ✓
  Drug product
- April 20, 2015
  ✓
  Pediatric exclusivity

Aripiprazole oral solution
Patent 6,977,257
Issued: December 20, 2005
Inventor(s): Parab; Prakash V. & Chou; Joyc Tianw i
Assignee(s): Bristol-Myers Squibb Company
The present invention provides for a pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents and one or more agents selected from the group consisting of lactic acid, acetic acid, tartaric acid and citric acid, wherein said solution has a pH from 2.5 to 4.5.
Patent expiration dates:
- April 24, 2022
  ✓
  Drug substance
  ✓
  Drug product
- October 24, 2022
  ✓
  Pediatric exclusivity

Aripiprazole complex formulation and method
Patent 7,115,587
Issued: October 3, 2006
Inventor(s): Nerurkar; Manoj & Naringrekar; Vijay
Assignee(s): Bristol-Myers Squibb Company
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Patent expiration dates:
- July 21, 2024
  ✓
  Patent use: TREATMENT OF SCHIZOPHRENIA
  ✓
  Drug substance
  ✓
  Drug product
- January 21, 2025
  ✓
  Pediatric exclusivity

Aripiprazole complex formulation and method
Patent 7,550,445
Issued: June 23, 2009
Inventor(s): Nerurkar; Manoj & Naringrekar; Vijay
Assignee(s): Bristol-Myers Squibb Company
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Patent expiration dates:
- July 21, 2024
  ✓
  Drug product
- January 21, 2025
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- October 29, 2010 - TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
- November 16, 2010 - ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- February 27, 2011 - TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
- April 29, 2011 - PEDIATRIC EXCLUSIVITY
- May 6, 2011 - STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- May 6, 2011 - ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- August 27, 2011 - PEDIATRIC EXCLUSIVITY
- November 19, 2012 - TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- February 16, 2014 - MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

Thursday, September 15, 2016

Marcaine

Marcaine is a brand name of bupivacaine, approved by the FDA in the following formulation(s):

MARCAINE (bupivacaine hydrochloride - injectable; spinal)

Manufacturer: HOSPIRA

Approval date: May 4, 1984

Strength(s): 0.75% ^[RLD]^[AP]

Has a generic version of Marcaine been approved?

Yes. The following products are equivalent to Marcaine:

SENSORCAINE (bupivacaine hydrochloride injectable; spinal)

Manufacturer: APP PHARMS

Approval date: April 15, 1987

Strength(s): 0.75% ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Marcaine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Marcaine.

Has a generic version of Humalog Mix 50/50 been approved?

No. There is currently no therapeutically equivalent version of Humalog Mix 50/50 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 50/50. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Monomeric insulin analog formulations
Patent 5,461,031
Issued: October 24, 1995
Inventor(s): De Felippis; Michael R.
Assignee(s): Eli Lilly and Company
The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Patent expiration dates:
- June 26, 2014

Insulin analog formulations
Patent 5,474,978
Issued: December 12, 1995
Inventor(s): Bakaysa; Diane L. & Brems; David N. & Frank; Bruce H. & Havel; Henry A. & Pekar; Allen H.
Assignee(s): Eli Lilly and Company
The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
Patent expiration dates:
- June 16, 2014

Insulin analogs modified at position 29 of the B chain
Patent 5,514,646
Issued: May 7, 1996
Inventor(s): Chance; Ronald E. & DiMarchi; Richard D. & Frank; Bruce H. & Shields; James E.
Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
Patent expiration dates:
- May 7, 2013

Monomeric insulin analog formulations
Patent 5,747,642
Issued: May 5, 1998
Inventor(s): De Felippis; Michael R.
Assignee(s): Eli Lilly and Company
The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Patent expiration dates:
- June 16, 2014

Has a generic version of Aygestin been approved?

Yes. The following products are equivalent to Aygestin:

norethindrone acetate tablet; oral

Manufacturer: BARR

Approval date: May 25, 2001

Strength(s): 5MG ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: July 21, 2010

Strength(s): 5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aygestin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Aygestin.

Has a generic version of Atacand HCT been approved?

No. There is currently no therapeutically equivalent version of Atacand HCT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atacand HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-c arboxylate and compositions and methods of pharmaceutical use thereof
Patent 5,196,444
Issued: March 23, 1993
Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
Assignee(s): Takeda Chemical Industries, Ltd.
1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-car boxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
Patent expiration dates:
- June 4, 2012
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug substance
  ✓
  Drug product
- December 4, 2012
  ✓
  Pediatric exclusivity

Pharmaceutical compositions for oral use and method of preparing them
Patent 5,534,534
Issued: July 9, 1996
Inventor(s): Makino; Tadashi & Mizukami; Yashio & Kikuta; Jun-ichi
Assignee(s): Takeda Chemical Industries, Ltd.
A pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) having antagonistic action to angiotensin II ##STR1## (wherein the ring W is an optionally substituted N-containing heterocyclic residue; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2) and an oily substance having a lower melting point, and a method for preparing a pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) and an oily substance having a lower melting point, which comprises admixing the compound of the formula (I) with an oily substance having a lower melting point and then subjecting the mixture to molding.
Patent expiration dates:
- July 9, 2013
  ✓
  Drug product
- January 9, 2014
  ✓
  Pediatric exclusivity

Benzimidazole derivatives and use thereof
Patent 5,705,517
Issued: January 6, 1998
Inventor(s): Naka; Takehiko & Nishikawa; Kohei
Assignee(s): Takeda Chemical Industries, Ltd.
Benzimidazole derivatives of the formula (I): ##STR1## wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R' group; R' is hydrogen or an optionally substituted hydrocarbon residue; R.sup.2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R' is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is --O--, --S(O).sub.m -- or --N(R.sup.4)-- wherein m is an integer of 0, 1 or 2 and R.sup.4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
Patent expiration dates:
- October 18, 2011
  ✓
  Pediatric exclusivity

Pharmaceutical composition for angiotensin II-mediated diseases
Patent 5,721,263
Issued: February 24, 1998
Inventor(s): Inada; Yoshiyuki & Kubo; Keiji
Assignee(s): Takeda Chemical Industries, Ltd.
This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m-- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
Patent expiration dates:
- February 24, 2015
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug product

Pharmaceutical composition for angiotensin II-mediated diseases
Patent 5,958,961
Issued: September 28, 1999
Inventor(s): Inada; Yoshiyuki & Kubo; Keiji
Assignee(s): Takeda Chemical Industries, Ltd.
This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
Patent expiration dates:
- June 6, 2014
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug product

Benzimidazole derivatives, their production and use
Patent 7,538,133
Issued: May 26, 2009
Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
Assignee(s): Takeda Pharmaceutical Company Limited
Benzimidazole derivatives of the formula (I): wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R1 is hydrogen or an optionally substituted hydrocarbon residue; R2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O)m— or —N(R4)— wherein m is an integer of 0, 1 or 2 and R4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
Patent expiration dates:
- October 18, 2011
  ✓
  Pediatric exclusivity

Friday, September 16, 2016

PEPCID (famotidine - for suspension; oral)

PEPCID (famotidine - tablet; oral)

Has a generic version of Pepcid been approved?

famotidine for suspension; oral

famotidine tablet; oral

Related Patents

See also...

H.P. ACTHAR GEL (corticotropin - injectable; injection)

Has a generic version of H.P. Acthar Gel been approved?

Related Patents

Related Exclusivities

See also...

THALITONE (chlorthalidone - tablet; oral)

Has a generic version of Thalitone been approved?

Related Patents

See also...

ANAPROX DS (naproxen sodium - tablet; oral)

Has a generic version of Anaprox-DS been approved?

naproxen sodium tablet; oral

Related Patents

See also...

ACUVAIL (ketorolac tromethamine - solution/drops; ophthalmic)

Has a generic version of Acuvail been approved?

Related Patents

Related Exclusivities

See also...

OFIRMEV (acetaminophen - solution; iv (infusion))

Has a generic version of Ofirmev been approved?

Related Patents

Related Exclusivities

See also...

OMNIPAQUE 240 (iohexol - solution; injection, oral, rectal)

Has a generic version of Omnipaque 240 been approved?

Related Patents

See also...

OPTIRAY 320 (ioversol - injectable; injection)

Has a generic version of Optiray 320 been approved?

Related Patents

See also...

HUMATROPE (somatropin recombinant - injectable; injection)

Has a generic version of Humatrope been approved?

Related Patents

Related Exclusivities

See also...

HUMALOG MIX 75/25 (insulin lispro protamine recombinant; insulin lispro recombinant - injectable; injection)

Has a generic version of Humalog Mix 75/25 been approved?

Related Patents

See also...

HUMALOG MIX 75/25 PEN (insulin lispro protamine recombinant; insulin lispro recombinant - injectable; injection)

Has a generic version of Humalog Mix 75/25 Pen been approved?

Related Patents

See also...

ANTIVERT (meclizine hydrochloride - tablet; oral)

Has a generic version of Antivert been approved?

meclizine hydrochloride tablet; oral

Related Patents

See also...

ALLEGRA (fexofenadine hydrochloride - suspension; oral)

Has a generic version of Allegra been approved?

Related Patents

See also...

MINIRIN (desmopressin acetate - spray, metered; nasal)

Has a generic version of Minirin been approved?

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) (desmopressin acetate spray, metered; nasal)

Related Patents

See also...

PREFEST (estradiol; norgestimate - tablet; oral)

Has a generic version of Prefest been approved?

ESTRADIOL AND NORGESTIMATE (estradiol; norgestimate tablet; oral)

Related Patents

See also...

ALPHAGAN P (brimonidine tartrate - solution/drops; ophthalmic)

Has a generic version of Alphagan P been approved?

brimonidine tartrate solution/drops; ophthalmic

Related Patents

See also...

AMMONUL (sodium benzoate; sodium phenylacetate - solution; iv (infusion))

Has a generic version of Ammonul been approved?

Related Patents